

Reports List » Response Report

**Global Academy - PRD2016 - Objectives Evaluation**

Likert Avg.  
**4.27**

Total Completed: 222

Options: Show Extended View

**Question 1.**

Having completed this activity, you are better able to:

Integrate into daily practice new clinical developments and up-to-date guidelines for the management of rheumatoid arthritis (RA) and other immune-mediated inflammatory rheumatologic diseases.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.347		± 0.878
Response	Count	Graph	Percent †
1=Strongly Disagree	6		3%
2	3		1%
3	15		7%
4	82		37%
5=Strongly Agree	116		52%
<b>Total Responses:</b>	<b>222</b>		

[Respondent Details](#) [Trend Analysis](#)

Outline the current and emerging therapeutic options that target established and newly recognized pathways in the pathogenesis of psoriasis and psoriatic arthritis.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.401		± 0.811
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	2		< 1%
3	10		5%
4	87		39%
5=Strongly Agree	118		53%

<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>
-------------------------	------------	---

Evaluate the safety and efficacy of the various classes of biologic agents in RA and other immune-mediated inflammatory rheumatologic diseases.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.275		± 0.918
Response	Count	Graph	Percent †
1=Strongly Disagree	6		3%
2	4		2%
3	23		10%
4	79		36%
5=Strongly Agree	110		50%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Identify skin manifestations of inflammatory disease.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.387		± 0.863
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	3		1%
3	17		8%
4	73		33%
5=Strongly Agree	124		56%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Implement strategies for lipid management in patients with inflammatory diseases.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.248		± 0.916
Response	Count	Graph	Percent †
1=Strongly Disagree	6		3%

2	4		2%
3	24		11%
4	83		37%
5=Strongly Agree	105		47%
<b>Total Responses:</b>	<b>222</b>	Respondent Details Trend Analysis	

Analyze RA-associated interstitial lung disease including pathogenesis and treatment.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.252		± 0.887
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	4		2%
3	30		14%
4	78		35%
5=Strongly Agree	106		48%
<b>Total Responses:</b>	<b>222</b>	Respondent Details Trend Analysis	

Compare and contrast the efficacy and safety profiles of pharmacologic treatment options for patients with polymyalgia rheumatica and other age-related musculoskeletal disease.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.221		± 0.971
Response	Count	Graph	Percent †
1=Strongly Disagree	7		3%
2	6		3%
3	25		11%
4	77		35%
5=Strongly Agree	107		48%
<b>Total Responses:</b>	<b>222</b>	Respondent Details Trend Analysis	

Recognize viral causes of rheumatic disorders to institute appropriate therapy.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.243		± 0.895
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	4		2%
3	26		12%
4	84		38%
5=Strongly Agree	103		46%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Evaluate and, when appropriate, incorporate the use of newer agents for the treatment of hyperuricemia and gout as they become available.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.297		± 0.913
Response	Count	Graph	Percent †
1=Strongly Disagree	6		3%
2	3		1%
3	24		11%
4	75		34%
5=Strongly Agree	114		51%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Recognize the signs and symptoms of lupus and incorporate into patient care new and emerging treatment options.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.347		± 0.893
Response	Count	Graph	Percent †
1=Strongly Disagree	7		3%
2	1		< 1%
3	18		8%

4	78		35%
5=Strongly Agree	118		53%
<b>Total Responses:</b>	<b>222</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>

Implement a strategy for incorporating newer agents into the roster of treatment options for patients with scleroderma and lung diseases.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.158		± 0.997
Response	Count	Graph	Percent †
1=Strongly Disagree	7		3%
2	8		4%
3	29		13%
4	77		35%
5=Strongly Agree	101		45%
<b>Total Responses:</b>	<b>222</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>

Describe skin reactions to medications used in rheumatic patients.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.279		± 0.953
Response	Count	Graph	Percent †
1=Strongly Disagree	8		4%
2	4		2%
3	18		8%
4	80		36%
5=Strongly Agree	112		50%
<b>Total Responses:</b>	<b>222</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>

Develop individualized strategies for pain management in patients with immune-mediated inflammatory rheumatologic diseases including recognizing new pain pathways.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
--------	------	-------	-----------

Response	Count	Graph	Percent †
All Respondents	4.248		± 0.896
1=Strongly Disagree	6		3%
2	3		1%
3	23		10%
4	88		40%
5=Strongly Agree	102		46%
<b>Total Responses:</b>	<b>222</b>		

Respondent Details Trend Analysis

Implement a treatment plan for rheumatic patients with gastrointestinal-related disorders.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.176		± 0.966
Response	Count	Graph	Percent †
1=Strongly Disagree	7		3%
2	4		2%
3	33		15%
4	77		35%
5=Strongly Agree	101		45%
<b>Total Responses:</b>	<b>222</b>		

Respondent Details Trend Analysis


Utilize enhanced practice management techniques and tools to increase office efficacy and facilitate patient care.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.180		± 0.977
Response	Count	Graph	Percent †
1=Strongly Disagree	6		3%
2	7		3%
3	32		14%
4	73		33%
5=Strongly Agree	104		47%
<b>Total Responses:</b>	<b>222</b>		

Respondent Details Trend Analysis

**Question 2.**

If you do not feel confident that you can achieve the above objectives to some extent, please describe why not.

Response	Count	Graph	Percent †
Open-ended Text Responses (View Responses)	25		100%
Non-Responders:	197		

**Legend**



**percent question responses**

Proportion of a specific response (Qa) to the sum of all responses provided for that question (Qt).

*percent of total question responses = Qa / Qt*

(Example: X% of all responses to question Y were "A".)

† Percentages are calculated in three different ways. Click on the "Show Extended View" option at the top of the report to display the additional calculations. In cases where a question is required and only one response is allowed, all three percentages will be equal. The difference between the three calculations is most notable in a choose-all-that-apply question type that is optional.

Reports List » Response Report

**Global Academy - PRD2016 - Speaker Evaluation**

Likert Avg.  
**4.93**

Total Completed: 222

Options: Show Extended View

**Question 1.**  
**Friday, September 16, 2016**

**Rheumatoid Arthritis (RA): Update on New Developments in Treatment • Iain B. McInnes, FRCP, PhD, FRSE, FMedSci**

Dr. McInnes was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.955		± 0.834
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	0		0%
3	7		3%
4	21		9%
5	149		67%
6=NA	41		18%
<b>Total Responses:</b>	<b>222</b>		

[Respondent Details](#) [Trend Analysis](#)

**RA Interstitial Lung Disease: Pathogenesis and Treatment • Jon T. Giles, MD, MPH**

Dr. Giles was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.725		± 0.952
Response	Count	Graph	Percent †



1=Strongly Disagree	4		2%
2	3		1%
3	13		6%
4	42		19%
5	128		58%
6=NA	32		14%
<b>Total Responses:</b>	<b>222</b>		

[Respondent Details](#) [Trend Analysis](#)

### Immunogenicity and Side Effects in RA • Daniel E. Furst, MD

Dr. Furst was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.766		± 0.974
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	3		1%
3	9		4%
4	42		19%
5	126		57%
6=NA	37		17%
<b>Total Responses:</b>	<b>222</b>		

[Respondent Details](#) [Trend Analysis](#)

### Panel Discussion

Panelists were effective presenters

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.833		± 0.884
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	0		0%

3	9		4%
4	41		18%
5	130		59%
6=NA	38		17%
<b>Total Responses:</b>	<b>222</b>		Respondent Details Trend Analysis

**Managing Pain in Rheumatic Diseases • Daniel J. Clauw, MD**

Dr. Furst was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.883		± 0.890
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	1		< 1%
3	6		3%
4	38		17%
5	130		59%
6=NA	43		19%
<b>Total Responses:</b>	<b>222</b>		Respondent Details Trend Analysis

**Viral Causes of Rheumatic Syndromes • Leonard H. Calabrese, DO**

Dr. Calabrese was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.892		± 0.901
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	0		0%
3	10		5%

4	33		15%
5	130		59%
6=NA	45		20%
<b>Total Responses:</b>	<b>222</b>	Respondent Details Trend Analysis	

**Lupus: Diagnosis and Treatment • Michelle Petri, MD, MPH**

Dr. Petri was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.973		± 0.866
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	0		0%
3	6		3%
4	28		13%
5	134		60%
6=NA	50		23%
<b>Total Responses:</b>	<b>222</b>	Respondent Details Trend Analysis	

**Panel Discussion**

Panelists were effective presenters

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.878		± 0.850
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	0		0%
3	4		2%
4	43		19%

5	131		59%
6=NA	40		18%
<b>Total Responses:</b>	<b>222</b>		Respondent Details Trend Analysis

**Rheumatology Workshop Track**

**Practical Approach to Shared Care for Psoriatic Arthritis • Iain B. McInnes, FRCP, PhD, FRSE, FMedSci**

Dr. McInnes was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	5.063		± 0.910
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%
3	3		1%
4	26		12%
5	122		55%
6=NA	66		30%
<b>Total Responses:</b>	<b>222</b>		Respondent Details Trend Analysis

**Scleroderma, GI and Lung Issues • Daniel E. Furst, MD**

Dr. Furst was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.973		± 1.002
Response	Count	Graph	Percent †
1=Strongly Disagree	6		3%
2	0		0%
3	8		4%
4	30		14%

5	114		51%
6=NA	64		29%
<b>Total Responses:</b>	<b>222</b>		Respondent Details Trend Analysis

**Polymyalgia Rheumatica (PMR) and Other Geriatric Challenges • Robert F. Spiera, MD**

Dr. Spiera was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	5.000		± 0.937
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%
3	6		3%
4	29		13%
5	121		55%
6=NA	61		27%
<b>Total Responses:</b>	<b>222</b>		Respondent Details Trend Analysis

**Primary Care Workshop**

**Psoriatic Arthritis and Psoriasis-Differential Diagnosis: The Derm Perspective • Kenneth B. Gordon, MD**

Dr. Gordon was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	5.117		± 0.885
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	0		0%
3	3		1%
4	26		12%

5	115		52%
6=NA	74		33%
<b>Total Responses:</b>	<b>222</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>

**Pain Management: Charting the Course • Daniel J. Clauw, MD**

Dr. Clauw was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)


Sample	Mean	Graph	Std. Dev.
All Respondents	5.045		± 0.926
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	1		< 1%
3	4		2%
4	32		14%
5	112		50%
6=NA	69		31%
<b>Total Responses:</b>	<b>222</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>

**Pattern Recognition and the Diagnosis of Arthritis • Brian Mandell, MD, PhD**

Dr. Mandell was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)








Sample	Mean	Graph	Std. Dev.
All Respondents	5.059		± 0.961
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%
3	6		3%
4	28		13%
5	110		50%
6=NA	73		33%

			
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a>	<a href="#">Trend Analysis</a>

### Clinical Case Conundrums: Stump the Professors

Speakers were effective presenters

(1=Strongly Disagree,5=Strongly Agree, 6=NA)







Sample	Mean	Graph	Std. Dev.
All Respondents	4.914		± 0.931
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	0		0%
3	7		3%
4	35		16%
5	125		56%
6=NA	50		23%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a>	<a href="#">Trend Analysis</a>

### Question 2. Saturday, September 17, 2016

#### Psoriasis: New and Emerging Developments • Kenneth B. Gordon, MD

Dr. Gordon was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.914		± 0.805
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	0		0%
3	2		< 1%
4	36		16%
5	143		64%

6=NA	37		17%
<b>Total Responses:</b>	<b>222</b>	Respondent Details Trend Analysis	

**Psoriatic Arthritis: The Latest Treatment Options • Iain B. McInnes, FRCP, PhD, FRSE, FMedSci**

Dr. McInnes was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.941		± 0.841
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	0		0%
3	6		3%
4	27		12%
5	143		64%
6=NA	42		19%
<b>Total Responses:</b>	<b>222</b>	Respondent Details Trend Analysis	

**Skin Reactions to Drugs • Ruth Ann Vleugels, MD, MPH**

Dr. Vleugels was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	5.005		± 0.859
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	1		< 1%
3	4		2%
4	23		10%
5	139		63%
6=NA	51		23%










<b>Total Responses:</b>	<b>222</b>	Respondent Details	Trend Analysis
-------------------------	------------	--------------------	----------------

**Panel Discussion**

Panelists were effective presenters








(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.883		± 0.848
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	0		0%
3	5		2%
4	39		18%
5	135		61%
6=NA	39		18%
<b>Total Responses:</b>	<b>222</b>	Respondent Details	Trend Analysis

**Co-morbidities: Lipid Management in Inflammatory Diseases • Jon T. Giles, MD, MPH**

Dr. Giles was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.815		± 0.891
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	1		< 1%
3	8		4%
4	42		19%
5	131		59%
6=NA	36		16%
<b>Total Responses:</b>	<b>222</b>	Respondent Details	Trend Analysis

## Connective Autoimmune Diseases: Pearls from the Rheum/Derm Clinic • Ruth Ann Vleugels, MD, MPH

Dr. Vleugels was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.964		± 0.834
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	0		0%
3	5		2%
4	26		12%
5	143		64%
6=NA	44		20%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a>	<a href="#">Trend Analysis</a>

### Panel Discussion

Panelists were effective presenters

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.869		± 0.854
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	0		0%
3	6		3%
4	39		18%
5	135		61%
6=NA	38		17%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a>	<a href="#">Trend Analysis</a>

**Treatment of an Ancient Disease: Treating Gout with Current and Emerging Therapies • Brian Mandell, MD, PhD**

Dr. Mandell was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.932		± 0.867
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	0		0%
3	7		3%
4	30		14%
5	136		61%
6=NA	45		20%
<b>Total Responses:</b>	<b>222</b>		

Respondent Details Trend Analysis

**Practical Pearls in Diagnosis and Management of GI-Related Issues in the Rheumatic Patient • Ali Rezaie, MD, MSc, FRCPC**

Dr. Rezaie was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.874		± 0.962
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	3		1%
3	8		4%
4	36		16%
5	122		55%
6=NA	49		22%
<b>Total Responses:</b>	<b>222</b>		

Respondent Details Trend Analysis

**Managing Your Practice: Pearls and Tips • Joseph S. Eastern, MD**

Dr. Eastern was an effective presenter

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.874		± 0.923
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	1		< 1%
3	10		5%
4	34		15%
5	128		58%
6=NA	45		20%
<b>Total Responses:</b>	<b>222</b>		

[Respondent Details](#) [Trend Analysis](#)

**Panel Discussion**

Panelists were effective presenters

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.914		± 0.935
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	1		< 1%
3	9		4%
4	34		15%
5	122		55%
6=NA	52		23%
<b>Total Responses:</b>	<b>222</b>		

[Respondent Details](#) [Trend Analysis](#)

**Clinical Case Conundrums: Stump the Professors**

Speakers were effective presenters

(1=Strongly Disagree,5=Strongly Agree, 6=NA)

Sample	Mean	Graph	Std. Dev.
All Respondents	5.000		± 0.882
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	0		0%
3	6		3%
4	28		13%
5	128		58%
6=NA	56		25%
<b>Total Responses:</b>	<b>222</b>		

Respondent Details Trend Analysis

**Question 3.**

If you requested ADA accommodations, were they met to your satisfaction?

Response	Count	Graph	Percent †
Not applicable	201		91%
Yes	19		9%
No	2		< 1%
<b>Total Responses:</b>	<b>222</b>		

Respondent Details Trend Analysis

**Question 4.**

If no, please explain:



Response	Count	Graph	Percent †
Open-ended Text Responses (View Responses)	5		100%
Non-Responders:	217		

**Question 5.**

**Pharmacists please record your attendance at the conference by answering the following 3 questions.**



**ONLY Pharmacists Must Answer (CPE Monitor):** Did you attend all Friday morning (Sept 16) didactic presentations (5.25 Contact Hours)?

Response	Count	Graph	Percent †
----------	-------	-------	-----------

Yes	11		79%
No	3		21%
<b>Total Responses:</b>	<b>14</b>		Respondent Details Trend Analysis
<i>Non-Responders:</i>	208		







**Question 6.**

**ONLY Pharmacists Must Answer (CPE Monitor):** Did you attend one of the Friday afternoon (Sept 16) breakout tracks (2.25 Contact Hours)?

Response	Count	Graph	Percent †
Yes	11		85%
No	2		15%
<b>Total Responses:</b>	<b>13</b>		Respondent Details Trend Analysis
<i>Non-Responders:</i>	209		



**Question 7.**

**ONLY Pharmacists Must Answer (CPE Monitor):** Which breakout sessions did you attend? Select the 3 that apply to you.

Response	Count	Graph	Percent †
Rheumatology Track: Psoriatic Arthritis	7		27%
Rheumatology Track: Scleroderma	6		23%
Rheumatology Track: Polymyalgia Rheumatica	7		27%
Primary Care Track: Psoriatic Arthritis & Psoriasis	2		8%
Primary Care Track: Pain Management	2		8%
Primary Care Track: Pattern Recognition & the Diagnosis of Arthritis	2		8%
<b>Total Responses:</b>	<b>26</b>		Respondent Details Trend Analysis
<i>Non-Responders:</i>	213		

**Question 8.**

**ONLY Pharmacists Must Answer (CPE Monitor):** Did you attend all the Saturday (Sept 17) didactic presentations (6.25 Contact Hours)?

Response	Count	Graph	Percent †
Yes	8		80%
No	2		20%
<b>Total Responses:</b>	<b>10</b>		Respondent Details Trend Analysis
<i>Non-Responders:</i>	212		

**Legend****percent question responses**

Proportion of a specific response (Qa) to the sum of all responses provided for that question (Qt).

*percent of total question responses =  $Qa / Qt$*

(Example: X% of all responses to question Y were "A".)

† Percentages are calculated in three different ways. Click on the "Show Extended View" option at the top of the report to display the additional calculations. In cases where a question is required and only one response is allowed, all three percentages will be equal. The difference between the three calculations is most notable in a choose-all-that-apply question type that is optional.

Manage Your Program:

PRD2016

Sh  
der, y  
017  
/ Jones  
Sign out]  
2:59 AM

Reports List » Response Report

## Global Academy - July 2016 Revised Shared Rutgers Activity Evaluation

Likert Avg.  
**4.39**

Total Completed: 222

Options: Show Extended View

**Question 1.**

Based on the content of the activity, what will you do differently in the care of your patients and/or regarding your professional responsibilities? (Select one)

Response	Count	Graph	Percent †
Implement a change in my practice/workplace.	69		31%
Seek additional information on this topic.	53		24%
Implement a change in my practice/workplace and seek additional information on this topic.	56		25%
Do nothing differently. Current practice/job responsibilities reflect activity recommendations.	40		18%
Do nothing differently. Content was not convincing.	0		0%
Do nothing differently. System barriers prevent me from changing my practice/workplace.	4		2%
<b>Total Responses:</b>	<b>222</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 2.**

If you anticipate changing one or more aspects of your practice and/or professional responsibilities as a result of your participation in this activity, please briefly describe how you plan to do so.

Response	Count	Graph	Percent †
Open-ended Text Responses (View Responses)	82		100%
<i>Non-Responders:</i>	<i>140</i>		

**Question 3.**

If you plan to change your practice/professional responsibilities, may we contact you in 2 months to see how you are progressing?



Response	Count	Graph	Percent †
Yes	54		24%
No	104		47%
I don't plan to make a change	64		29%
<b>Total Responses:</b>	<b>222</b>		

[Respondent Details](#) [Trend Analysis](#)




**Question 4.**

Were the patient recommendations based on acceptable practices in medicine?

Response	Count	Graph	Percent †
Yes	221		100%
No	1		< 1%
<b>Total Responses:</b>	<b>222</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>



**Question 5.**

If no, please explain which recommendation(s) were not based on acceptable practices in medicine.

Response	Count	Graph	Percent †
Open-ended Text Responses (View Responses)	5		100%
<i>Non-Responders:</i>	217		


**Question 6.**

Do you think the presentations were without commercial bias and influence?

Response	Count	Graph	Percent †
Yes	213		96%
No	9		4%
<b>Total Responses:</b>	<b>222</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>

**Question 7.**


If no, please list the presentation(s) that were biased.

Response	Count	Graph	Percent †
Open-ended Text Responses (View Responses)	4		100%
<i>Non-Responders:</i>	218		

**Question 8.**

The presentations met my educational needs by:

This education increased my understanding of the subject.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.545		± 0.683

Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	0		0%
3	12		5%
4	69		31%
5=Strongly Agree	139		63%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

This education will influence how I do my job.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.315		± 0.856
Response	Count	Graph	Percent †
1=Strongly Disagree	3		1%
2	0		0%
3	39		18%
4	62		28%
5=Strongly Agree	118		53%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

This education will help me improve my job performance.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.374		± 0.784
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	0		0%
3	30		14%
4	71		32%
5=Strongly Agree	119		54%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

This education will help me collaborate with other healthcare professionals.  
 (1=Strongly Disagree,5=Strongly Agree)



Sample	Mean	Graph	Std. Dev.
All Respondents	4.360		± 0.816
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	2		< 1%
3	30		14%
4	68		31%
5=Strongly Agree	120		54%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a>	<a href="#">Trend Analysis</a>

This education addressed issues in cultural competency.  
 (1=Strongly Disagree,5=Strongly Agree)







Sample	Mean	Graph	Std. Dev.
All Respondents	4.036		± 0.974
Response	Count	Graph	Percent †
1=Strongly Disagree	4		2%
2	7		3%
3	56		25%
4	65		29%
5=Strongly Agree	90		41%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a>	<a href="#">Trend Analysis</a>

This education was educationally sound and scientifically balanced.  
 (1=Strongly Disagree,5=Strongly Agree)







Sample	Mean	Graph	Std. Dev.
All Respondents	4.559		± 0.682
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	0		0%
3	12		5%

4	66		30%
5=Strongly Agree	142		64%
<b>Total Responses:</b>	<b>222</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>

This education was free of commercial bias or influence  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.473		± 0.759
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	1		< 1%
3	21		9%
4	64		29%
5=Strongly Agree	134		60%
<b>Total Responses:</b>	<b>222</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>

This education met my expectations.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.509		± 0.729
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	0		0%
3	19		9%
4	63		28%
5=Strongly Agree	138		62%
<b>Total Responses:</b>	<b>222</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>

**Question 9.**

This activity should improve my:

Medical or Practice Knowledge  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.536		± 0.697
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	0		0%
3	14		6%
4	67		30%
5=Strongly Agree	139		63%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

## Care Attitudes

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.288		± 0.850
Response	Count	Graph	Percent †
1=Strongly Disagree	3		1%
2	1		< 1%
3	36		16%
4	71		32%
5=Strongly Agree	111		50%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

## Procedural or Cognitive Skills

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.279		± 0.831
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	4		2%
3	30		14%
4	80		36%
5=Strongly Agree	106		48%

<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a>	<a href="#">Trend Analysis</a>
-------------------------	------------	------------------------------------	--------------------------------

### Practice Behavior

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.270		± 0.834
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	2		< 1%
3	37		17%
4	74		33%
5=Strongly Agree	107		48%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a>	<a href="#">Trend Analysis</a>

### Patients' Clinical Outcomes

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.347		± 0.762
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	1		< 1%
3	24		11%
4	86		39%
5=Strongly Agree	109		49%
<b>Total Responses:</b>	<b>222</b>	<a href="#">Respondent Details</a>	<a href="#">Trend Analysis</a>

### Question 10.

Please indicate any primary barriers to implementing information acquired at the event to updating and/or redefining your patient care approach? (choose all that apply)

Response	Count	Graph	Percent †
Diagnostic tool/treatment limitation.	56		16%
Diagnostic tool/treatment unavailability.	52		14%
Patients decline diagnostic or treatment intervention.	57		16%

I don't feel confident in implementing this change.	5		1%
Lack of patient education.	29		8%
My practice doesn't permit this type of change.	30		8%
Lack of time to implement	51		14%
I need more education about this topic.	31		9%
Other (View Responses)	48		13%
<b>Total Responses:</b>	<b>359</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 11.**

How do you think these barriers could be eliminated?

Response	Count	Graph	Percent †
Open-ended Text Responses (View Responses)	222		100%

**Question 12.**

Please rate on a scale of 1 to 5.

(1=Poor, 2=Fair, 3=Average, 4=Good, 5=Excellent)

How would you rate this activity?  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.550		± 0.649

Response	Count	Graph	Percent †
1=Poor	0		0%
2	2		< 1%
3	13		6%
4	68		31%
5=Excellent	139		63%
<b>Total Responses:</b>	<b>222</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 13.**


What issues are you experiencing in your practice/regarding your professional responsibilities that could be addressed in future programming?

Response	Count	Graph	Percent †
Open-ended Text Responses (View Responses)	74		100%

<i>Non-Responders:</i>	148	
------------------------	-----	--

**Question 14.**

Please provide us with any additional comments you would like to make including suggestions for improvement. We welcome your feedback.

Response	Count	Graph	Percent †
Open-ended Text Responses (View Responses)	64		100%
<i>Non-Responders:</i>	158		

**Legend****percent question responses**

Proportion of a specific response ( $Qa$ ) to the sum of all responses provided for that question ( $Qt$ ).

$percent\ of\ total\ question\ responses = Qa / Qt$

(Example: X% of all responses to question Y were "A".)

† Percentages are calculated in three different ways. Click on the "Show Extended View" option at the top of the report to display the additional calculations. In cases where a question is required and only one response is allowed, all three percentages will be equal. The difference between the three calculations is most notable in a choose-all-that-apply question type that is optional.